A prominent new guideline for assessing and managing cardiovascular disease risk recommends a shift away from the long-standing practice of titrating statin therapy to meet targeted cholesterol levels. This controversial new paradigm and its underlying risk calculator have divided clinicians and laboratorians, so how extensively it will be adopted remains to be seen.
With a final guidance on how diagnostic companies can market research-use-only tests and instruments, FDA has drawn a line in the sand that could signal strict enforcement in the years ahead.
Because chronic infection with hepatitis B (HBV) or hepatitis C (HCV) initially presents with minimal symptoms, many chronically infected individuals do not discover their illness until they develop cirrhosis or liver cancer. Laboratorians should familiarize themselves with the many tests available for HBV and HCV, which are essential for detecting viral hepatitis in time to prevent these complications.
Download the entire issue